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Abs:                    Antibodies, pertaining to flow cytometry staining of certain epitope signatures 
 
ACK:                 Ammonium-Chloride-Potassium lysing buffer for erythrocyte removal 
 
ACT:                 Adoptive cellular therapy 
 
AICD:                Activation-induced cell death, results from T cell engagement with tumor 
 
ANV:                 Antigen-negative variant form of MMC with neu oncoprotein loss, cell line 
 
B/I + IL-2:         Bryostatin 1/ Ionomycin + Interleukin-2 at Day 0, initiates reprogramming 
 
B/I + γ-c:           Bryostatin 1/ Ionomycin + γ-chain cytokines (IL-2, IL-7, IL-15), for expansion  
 
DCIS:                Ductal carcinoma in situ, early slow growing form of mammary cancer 
 
DMSO:             Dimethyl Sulfoxide, prevents crystal formation upon freezing for cell viability 
 
EDTA:              Ethylenediaminetetraacetic acid, chelating agent for gentle adherent cell removal 
 
EMT:                 Epithelial to mesenchymal transition 
 
ER:                    Estrogen receptor 
 
FBS:                  Fetal bovine serum, growth supplement 
 
FITC:                 Fluorescein isothiocyanate, fluorochrome used with 488 nm-wavelength laser 
 
FVBN202:    Transgenic mouse model with an additional copy of rat neu oncoprotein  
                           inserted downstream of the MMTV promoter, resulting in neu overexpression 
 
GVHD:              Graft versus host disease; donor-mismatch issue in recipients resulting in illness 
 
HBSS:                Hank’s balanced salt solution; salt solution with glucose added for cell stability 
 
HER2/neu:         Human epidermal growth factor receptor 2/ neu oncoprotein 
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HPV:                  Human Papillomavirus; 100% effective prophylactic HPV vaccines produced  
 
IACUC:             Institutional animal care and use committee, VCU organization 
 
i.v.:                     Intravenous, injection or treatment delivery 
 
mANV:              Metastatic antigen-negative variant of MMC, established tumor cells in culture 
 
MCP-1/CCL2: Monocyte chemotactic protein 1 or chemokine (C-C motif) ligand 2,        
                           monocyte/macrophage macrophage chemoattractant associated with MMC 
 
MDSC:              Myeloid-derived suppressor cells, CDllb+ GR-1+ 
 
MET:                 Mesenchymal to epithelial transition 
 
MMC:                Mouse mammary carcinoma (neu-overexpressing), cell line 
 
mMMC:             Metastatic mouse mammary carcinoma, established tumor cells in culture 
 
MMP/MMP9:   Matrix metalloprotease; Matrix metalloprotease 9, TAM secreted and found in  
                           lung prior to metastasis               
 
MMTV:             Mouse mammary tumor virus 
 
MTT:                  3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide, indicator reagent 
 
NK/NKT:          Natural killer (CD3-CD49b+) or natural killer T cells (CD3+ CD49b+) 
 
n.s.:                    Not significant, statistically; p > 0.05  
 
PBS:                   Phosphate buffered saline solution (1X), washing solution 
 
PE:                     Phycoerythrin, fluorochrome (488 laser) 
 
PE/Cy5:             Phycoerythrin conjugated to Cy5 molecule, fluorochrome (488 laser) 
 
PI:                      Propidium iodide, used in viability studies to bind DNA indicating necrosis 
 
PR:                     Progesterone receptor 
 
s.c.:                    Subcutaneously tumor-challenged mice 
 
SEM:                  Standard error of the mean 
 
TN:                      Naïve (N) T cells, CD44-CD62L+ 
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TEM:                    Effector memory (EM) T cells, CD44+CD62L+(low) 
 
TCM:                    Central memory (CM) T cells, CD44+CD62L+(high) 
 
TE:                       Effector (E) T cells, CD44+CD62L- 
 
TAM:                 Tumor-associated macrophages, also known as M2 macrophages, Th2-skewed 
 
TGF-β1:             Transforming growth factor – beta, isoform 1; dual function cytokine for tumor 
 
TME:                 Tumor microenvironment 
 
VEGF:               Vascular endothelial growth factor, angiogenic soluble factor 
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Metastatic breast cancer treatment has seen few advances in recent years, yet treatment resistance 
continues to rise, causing disease recurrence. A pilot study was performed to determine the 
efficacy of ex vivo expansion and reprogramming of tumor-reactive immune cells from 
experimental metastatic tumor-sensitized mice. Also, phenotypic changes in tumors due to 
metastasis or tumor microenvironment influences were characterized. Metastatic neu+ mouse 
mammary carcinoma (mMMC) and its distant relapsing neu-antigen-negative variant (mANV) 
were investigated in FVBN202 mice. Tumor-reactive central memory CD8+ T cells and 
activated NK/NKT cells were successfully reprogrammed and expanded during 6-day expansion 
from mMMC- and/or mANV-sensitized mice, resulting in tumor-specific cytotoxicity. mMMC 
exhibited a flexible neu-expression pattern and acquired stem-like, tumorigenic phenotype 
following metastasis while mANV remained stable except decreased tumorigenicity. Myeloid-
derived suppressor cell (MDSC) levels were not increased. Adoptive cellular therapy (ACT) with 
reprogrammed tumor-reactive immune cells may prove effective prophylaxis against metastatic 






















The need for effective therapy against recurrent and metastatic breast cancer has been 
poorly addressed in recent years. The cancer-associated mortality from solid tumors due to 
metastatic disease has been estimated at 90% (1). As the overall numbers of patients with breast 
cancer decreases, the number of patients with advanced invasive breast cancers, refractory to 
conventional therapies, increases at a rate outpacing novel therapeutic development (1). In a 
study conducted from 1992 through 2007, a higher risk of death was associated with relapsed 
breast cancer patients following local treatment than in stage IV patients naïve to treatment, 
effectively separating these two groups for treatment considerations (2). Metastatic distant 
recurrent disease has been estimated in 2013 to occur in a quarter of breast cancer patients 
following adjuvant chemotherapy (3).	  As of this year, the estimated 24.3% 5-year rate of survival 
for women with distant metastatic disease at diagnosis is shockingly low when considering that 1 
in 8 U.S. women will develop invasive breast cancer in their lifetime (4). Breast carcinomas with 
HER2/neu protein overexpression (Estrogen Receptor(ER)-, Progesterone Receptor(PR)-) have 
been estimated to comprise 25-30% of total tumors compared to luminal A (ER+ and/or PR+, 
HER2-), luminal B (ER+ and/or PR+, HER2+) and triple-negative forms (roughly 10-15%) of 
cancer based on receptor expression (1, 5). Mittendorf et al. found that 1/3 of HER2/neu+ breast 
cancer patients receiving neoadjuvant Trastuzumab lost HER2/neu expression and those patients 
had a much lower rate of recurrence-free survival (5). Both HER2/neu+ and triple-negative 
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basal-like forms of breast cancer have been associated with a poor prognosis and higher risk of 
disease recurrence (3, 5-7). 
Metastasis has traditionally been thought of as a linear or parallel model of successful 
tumor relocation either sequentially or simultaneously with primary tumor growth within a 
patient (8). Metastases have demonstrated a tissue tropism in dissemination based on each 
primary neoplastic site that has become a signature for various forms of cancer according to a 
specific set of genes (9, 10). Breast cancer has demonstrated a preferential dissemination pattern 
to bone, lungs, brain and liver (10, 11). During dissemination, the tumors have been shown to 
undergo changes reminiscent of the embryogenic program of epithelial-to-mesenchymal 
transition (EMT) associated with progenitor cell trafficking during development and wound 
healing, along with the program reversal prior to secondary tumor establishment (MET). These 
EMT changes (12, 13) have major implications on adhesion, migration and ultimate survival that 
have been linked to a transition in breast carcinoma cells towards a stem-like phenotype 
(CD44+CD24-/low), originally discovered by Al Hajj et al. (14, 15).  
The idea of tumorigenic cancer stem cells in breast cancer has been associated with self-
renewal, enhanced tumor-initiation and treatment resistance (16-18). CD44 is an adhesion 
molecule found on the outside of most mammalian cells in various isoforms (often interacting 
with hyaluronic acid), involved specifically in rolling adhesion on activated lymphocytes and 
cell migration in other cells, including invasive metastatic tumor cells (19, 20). During metastatic 
disease progression, CD44 has been associated with the HER2 tyrosine kinase-signaling 
complex, indicating its importance in HER2/neu+ cells (20). CD24 is also an adhesion molecule 
found on many cell types that has been linked in breast cancer to p-selectin rolling adhesion and 
metastasis (21). The downregulation of CD24 during EMT has recently been linked to stress-
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induced autophagy in CD44+CD24-/low mesenchymal-like breast cancer stem-like cells, 
reversed with autophagy inhibition towards the original epithelial-like phenotype (22). 
Santisteban et al. showed that CD8-dependent EMT also could induce stemness in breast cancer 
cells (23). Xie et al. determined that pro-inflammatory IL-6 could induce EMT in breast cancer 
cells (24). When considering the connections of EMT being associated with stem cell migration 
during wound healing, breast cancer cell stemness phenotype induction and multiple pro-
inflammatory cytokines involved in the overall metastatic process, it is not surprising to consider 
the idea that progressive neoplasia has been associated with Th2-skewed chronic inflammation 
persisting in the tumor microenvironment (TME) instead of a productive Th1 anti-tumor 
response (25, 26).  
The TME and its many cellular constituents, including macrophages and fibroblasts, have 
been implicated as initiators of cancer cell dissemination through the production of matrix 
metalloproteases (MMP) or expression of soluble angiogenic factors, if tumor cells are not 
inherently metastatic themselves (11). The results of mammary tumor dissemination studies have 
also inherently linked the ideas of TME crosstalk, metastasis and tumor dormancy, where 
disseminated cells may either successfully metastasize or become dormant (27). The 
proliferation and tumorigenicity of dormant tumor cells in vitro may be recovered upon retrieval 
from an incompatible site of metastasis, devoid of macroscopic metastatic formation (27). Tumor 
dormancy has raised many questions not well addressed by recent therapeutic advances. 
Previously, patients have been reported to develop recurrent disease 25 years after primary tumor 
resection (28). These cells may have been altered during EMT or the pre-metastatic niche may be 
incompatible with their growth requirements inducing a quiescent state that may be reversed at a 
later time by some triggering event (29). 
	   4	  
Emerging uses for tumor immunotherapies have altered the way immunologists have 
approached the study of biologics in personalized healthcare. Trastuzumab and all related 
HER2/neu-specific passive immunotherapeutics introduced since 1998 have shown a positive 
effect of up to a 30% increase on ten-year overall survival and recurrence reduction up to 50% 
over previous chemotherapy regimens, especially in combination (5, 30). However when 
considering the distant recurrence-free interval following various treatments, little progress has 
been made in the past 30 years (3). Major advances to studies on metastasis have recently been 
made, including: mouse model developments (31), tracking tumors during the metastatic cascade 
(27, 32), monitoring disease progression and assessing the specific treatment effects of various 
therapies during the many steps of metastasis at different locations (11). But larger strides still 
need to be made in accurately quantifying phenotypic, genetic or epigenetic changes to the 
tumors as a result of metastasis in relation to immune responses.  
Adoptive cellular therapy (ACT) has been employed to treat tumors by immune cell 
infusion requiring a strong T cell response for resolution following ex vivo expansion of T cell 
subsets of interest and often lymphodepletion (33). Adoptive immunotherapy has had limited 
patient success in solid primary tumors apart from complete regression of highly-immunogenic 
melanoma (34), but the use of ACT of ex vivo reprogrammed tumor-reactive immune cells in 
metastatic stage IV or recurrent breast cancer has only recently been considered (35-38). Some 
major therapeutic challenges with aggressive breast tumors have been: treatment resistance 
(acquired following Trastuzumab), circulating tumor cells resulting in distant metastases, tumor 
dormancy, and HER2/neu receptor loss towards the basal-like triple-negative invasive form (5, 
11). Immunotherapy has had to overcome multiple treatment barriers also, including: low 
immunogenicity of tumors, immunosuppressive cells, low avidity/weak tumor-reactive immune 
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cell expansion and tumor stromal infiltration (33, 39). Immunosuppressive cells, like myeloid-
derived suppressor cells (MDSCs) and/or T regulatory cells, have been implied in 
immunoediting tumors towards recurrence and promoting metastasis in multiple breast cancer 
models (36, 40-46). Increases in MDSC levels have been correlated with metastatic breast cancer 
in 4T1 spontaneous lung metastatic and MDA-MB-231 lymph node metastatic mouse models 
(40, 43, 44, 47) along with our primary mouse mammary carcinoma (MMC) model following 
tumor-derived soluble factor release, like GM-CSF (48). In order to combat immune evasive 
techniques and effectively clear these moving targets from the vasculature or lymphatics 
following conventional therapy, new personalized treatment plans are needed to address the 
complexities associated with metastatic breast carcinoma. 
Our group has previously successfully reprogrammed tumor-reactive immune cells from 
FVBN202 mice (45, 46) towards a memory T cell and activated NK/NKT differentiated 
phenotype using Bryostatin 1 (49, 50) and Ionomycin (51, 52) with sequential common γ–chain 
cytokines (IL-2, IL-7 and IL-15) when challenged with MMC subcutaneously (s.c.) for use in 
prophylactic ACT of primary solid tumor. Ultimately, activated NK/NKT cells induced MDSC 
resistance and rescue of cytotoxic CD8+ T cell functions to produce tumor regression along with 
a memory response upon repeat challenge with primary tumors (46). Also, we have shown that 
IFN-γ treatments of MMC could induce relapse (HER2/neu loss) to an antigen-negative variant 
(ANV) by hypermethylation of the mouse mammary tumor virus (MMTV) promoter, directly 
epigenetically regulating HER2/neu and IFN-γRα expression (53). In our current study, we 
wanted to apply some of the techniques already described in a more clinically relevant model of 
therapy, metastatic or recurrent breast cancer. We compared neu-protein overexpressing MMC 
with relapsed ANV, similar to basal-like triple-negative invasive human breast cancer, prior to 
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and directly following metastatic cascade as a means to understand some of the therapeutic 
problems previously listed in a relevant immune setting, HER2/neu-overexpressing FVBN202 
transgenic mice.	  The objectives of the study were to: i) test the feasibility of ex vivo expansion 
and reprogramming of tumor-reactive immune cells from mMMC- or mANV-sensitized 
FVBN202 mice for determination of functional efficacy at cytotoxic tumor-killing in vitro, and 
ii) determine the role of metastatic cascade or microenvironment influences at inducing tumor 
phenotypic changes. Previously, our group (54) investigated the neu-specific anti-tumor immune 
response in the context of vaccine or ACT design. Disis and colleagues have also produced an 
effective peptide-based vaccine targeted at HER2/neu oncoprotein extracellular domains 
resulting in prolonged overall survival in concert with Trastuzumab treatment (55, 56). These 
immunotherapeutic strategies employed may be combined with drugs that target the pre-
metastatic niches to effect changes that may prove incompatible with the growth patterns of 
circulating tumor cells upon arrival at a secondary site (11). Our study elucidated the feasibility 
of ex vivo expansion and reprogramming of tumor-reactive immune cells with cytotoxic efficacy 
despite metastatic or TME influences. This assisted in the proposal of a new preventive treatment 
option for the future of synergistic, long-term metastatic breast cancer therapy, which may be 
initiated following conventional treatment of primary tumor instead of or possibly in addition to 

























FVBN-202 female transgenic mice (Charles River Laboratories) between the ages of 6 and 16 
weeks were used throughout these experiments. FVBN-202 mice overexpress the unactivated rat 
neu transgene in mammary glands under the control of MMTV promoter with the potential for 
pulmonary metastatic disease after long latency (57). The normal disease progression in older 
mice starts with pre-malignant hyperplasia most like ductal carcinoma in situ (DCIS) and 
increased endogenous myeloid-derived suppressor cell (MDSC) levels before spontaneous 
mammary carcinoma develops (54). All studies were reviewed and approved by the Institutional 
Animal Care and Use Committee (IACUC) at Virginia Commonwealth University.  
 
Tumor cell lines 
 
The neu overexpressing mouse mammary carcinoma (MMC) cell line was established from a 
spontaneous mammary tumor harvested from FVBN202 mice (58). The antigen negative variant 
(ANV) form was derived from MMC tumor cells under neu-specific immune pressure in 
Parental FVB mice (59). To establish experimental lung metastasis, mice were challenged with 1 
x 106 primary tumor cells by tail vein injection (i.v.) for 22-29 days based on changes in 
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moribundity or drops in weight. Lung metastases were surgically excised upon animal sacrifice 
under aseptic conditions. The lungs were photographed and finely minced prior to cold 
tryspinization with 0.25% Trypsin in HBSS for 12-16 hours at 4°C. Following overnight 
incubation, the cell suspension was gently vortexed and incubated for 30 minutes at 37°C, 5% 
CO2 prior to straining cells through 70 micron strainers (BD, San Jose, CA) for culture (60). 
Single cell suspensions were achieved with substantial mechanical disaggregation of clumps by 
pipetting cells with decreasing sized pipet tips for many minutes. Differential trypsinization over 
multiple passages allowed for tumor cell purification using 0.05% Trypsin in PBS for 3 minutes 
by fibroblast removal. Metastatic MMC (mMMC) and metastatic ANV (mANV) were 
established over a month supplemented with 20% FBS for purification/ fibroblast removal prior 
to full characterization. To test phenotypic changes acquired during metastasis, 3-5 x 106 
metastatic or control primary cells were inoculated by subcutaneous (s.c.) challenge into the 
groin region. Primary tumors from mice burdened with bulky mammary subcutaneous tumors 
were surgically excised upon animal sacrifice under aseptic conditions. Primary tumors (from 
previously established cell lines) were processed similar to metastatic lungs, except that the 
reisolated cells were only allowed to adhere to flasks for 3-5 days prior to flow cytometric 
analysis. Tumor cells were normally maintained in RPMI 1640 media supplemented with 10% 
FBS. Fold growth was determined by change in cell number from original optimal seeding 
amount (final cell number/ seeded cell number). Tumor cell passaging utilized 2.5 mM EDTA in 
PBS (mMMC & MMC) to minimize active suspension tumor aggregate formation or 0.25% 
Trypsin in HBSS (mANV & ANV) normally. All cell counts were performed with trypan blue 
exclusion for viability determination. Freezer stocks were created for future study of newly 
established metastatic cells (2 x 106 cells, 90% FBS + 10% DMSO). 
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Flow cytometry 
 
Flow cytometric analyses were performed as previously described by our group (46). Briefly, 
spleens or tumors were disaggregated into a single cell suspension (above) and 106 cells were 
aliquoted into each sample tube. Red blood cells were lysed for removal from spleens with ACK 
Buffer (Quality Biological, Gaithersburg, MD) and washed twice to purify viable cells. Non-
specific binding of antibodies (Abs) to Fc Receptors (FcR) was blocked by incubating the cells 
with anti-CD16/32 Ab on ice for 20 minutes per the manufacturer’s recommendation 
(BioLegend, San Diego, CA). Cells were stained with surface Abs toward various markers and 
incubated on ice in the dark for 20 min. The cells were then washed with cell staining buffer 
(PBS, 1% FBS, 0.1% sodium azide) and fixed with 1% formaldehyde. For Annexin V staining, 
cells were stained for respective surface markers, washed with cell staining buffer, and then 
washed with 1X Annexin V buffer (BD Pharmingen, San Jose, CA). The Annexin V and 
propidium iodide (PI) staining protocol given in the product data sheet was then followed. Abs 
used for flow cytometry were purchased from BioLegend (FITC- Goat anti-mouse IgG1, FITC-, 
PE/Cy5-CD3, PE/Cy5-, allophycocyanin-CD4, FITC-, PE-, PE/Cy5-CD8, FITC-, PE-CD11b, 
FITC-, PE-Gr1, FITC-, PE-CD25, PE-CD44, allophycocyanin-CD62L, allophycocyanin-CD49b, 
PE/Cy5-CD69, PE-CD122, and PE-CD127, PE/Cy5-CD24). All Abs were used at the 
manufacturer’s recommended concentrations. Multicolor data acquisition was performed 
immediately for viability studies or within 24 hours of fixation on a BD FACSCanto II. Analysis 
was performed using BD FACSDiva software or FlowJo Software (Treestar, Ashland, OR). 
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MTT proliferation assay 
 
MTT proliferation assay was performed according to the manufacturer’s protocol (Roche, 
Mannheim, Germany). An optimization plate revealed the most even proliferation from all cells 
was at a cell density of 5 x 103 cells per well. Tumor cells were plated on 96-well plates at 5 x 
103 cells per well for 48-hour culture at 37°C, 5% CO2 prior to addition of MTT reagent. MTT 
reagent was added for a 4-hour incubation for formazan crystal formation prior to overnight 
incubation with HCl solubilization solution. Samples were read on an ELISA plate reader at a 
wavelength of 540 nm and negative control wells that did not receive MTT were subtracted as 
reference to remove assay background absorbance. Five wells were plated for each cell type for 




Boyden chamber Matrigel (BD Biosciences, Bedford, MA) invasion assays were performed 
essentially as previously described (61). Cells in 200 uL growth media were added to cell culture 
inserts (0.8 µm pore) coated with Matrigel (diluted 1:6 in cell growth medium, dried for 30 min. 
at 37°C, 5% CO2) on a 24 well plate (BD Falcon, Franklin, NJ) and 300 uL growth media was 
added to the lower chamber. Analysis of invading tumor cells consisted of seeding the cells at 2 
x 104 – 1 x 105 cells per well for 48 hour culture at 37°C, 5% CO2. Tumors were tested for 
presence or absence of Matrigel invasiveness following fixation with 5% Glutaraldehyde (Ted 
Pella, Redding, CA) and toluidine blue staining (0.5%). Assessment of the ability to invade at 
different concentrations was determined by picture representations of each cell type. 
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Ex vivo expansion of tumor-sensitized immune cells from FVBN202 mice 
 
FVBN202 transgenic mice were injected intravenously (i.v.) with tumor cells, and splenocytes 
were harvested after 16–29 days based on tumor burden or weight loss/ moribundity in 
experimental metastatic mice. Tumor growth from subcutaneous inoculation was monitored by 
digital calipers, and tumor volumes were calculated by volume (v) = (L [length] × W [width]2)/2. 
Splenocytes (106 cells/ml) were stimulated upon harvest in complete medium (RPMI 1640 
supplemented with 100 U/ml penicillin, 100 mg/ml streptomycin, 10% FBS, 10 mM L-
glutamine) containing 10% FBS as well as bryostatin 1 (5 nM)/ionomycin (1 µM), and 80 U/ml 
IL-2 for 16 h (B/I + IL-2), as previously described by our group (46). Cells were then washed 
three times and cultured at 106 cells/ml in complete medium with 20 ng/ml each of common γ-
chain cytokines (γ-c), IL-7 and IL-15 (PeproTech, Rocky Hill, NJ). After 24 h, 20 U/ml IL-2 was 
added to the culture. On the next day, cells were washed three times and cultured at 106 cells/ml 
in complete medium with 40 U/ml IL-2. Cells were counted and cultured as before with 40 U/ml 




ELISA was performed as previously described by our group (46). Briefly, ex vivo expanded 
tumor-primed splenocytes were cultured in complete medium at a ratio of 10:1 with irradiated 
MMC, mMMC, ANV or mANV cells (14,000 rad) for 24 h. Supernatants were collected and 
stored at -80°C until assayed. IFN-γ was detected using a Mouse IFN-γ ELISA kit (BD 
Pharmingen, San Jose, CA) according to the manufacturer’s protocol. 
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Cytotoxicity assay 
 
In vitro cytotoxicity assay was performed as previously described by our group (46). Briefly, ex 
vivo expanded tumor-primed splenocytes were cultured with MMC, mMMC, ANV or mANV 
cells at a 10:1 E:T ratio in 5 ml growth medium with 20 U/ml IL-2 (PeproTech, Rocky Hill, NJ) 
in 60 x15 mm individual culture dishes (Greiner). After 48 h, cells were harvested and stained 
for neu (anti–c-Erb2/c-Neu; Calbiochem, San Diego, CA), CD3, Annexin V, and PI according to 
the manufacturer’s protocol (Biolegend, San Diego, CA). Flow cytometry was used to analyze 
the viability of neu+ MMC or mMMC, CD3- Tumors (all four) or CD3+ T cells for clear 




Graphical data are presented as means with standard errors (SEM) where possible. Statistical 
comparisons between groups were made using paired (treated) or unpaired (untreated) one-tailed, 




















Lung metastatic mMMC and mANV exhibited enhanced proliferation and a similar morphology 
compared to primary MMC and ANV tumor cells 
 
Upon experimental lung metastasis of neu positive mouse mammary carcinoma (MMC) 
and its relapsing neu antigen negative variant (ANV), mMMC and mANV tumor cell lines were 
established for characterization of phenotypic changes following the metastatic cascade. As seen 
in Figure 1A, lung metastatic disease induced by intravenous injection of MMC or ANV showed 
significant macro-metastatic pulmonary disease. Growth of mMMC resulted in diffuse bulky 
tumor formation in the lungs within 23.6 days on average (n=5). The nodular growth of mANV 
resulted in pronounced lung deterioration and clotting upon sacrifice within 28.5 days on average 
(n=2). The time for macrometastasis formation in the lung requiring sacrifice (Figure 1B) was 
significantly shorter in FVBN202 mice bearing MMC compared to mice bearing ANV 
(p=0.002). Significant increases in proliferation of the metastatic cells were shown in Figure 1C 
by MTT assay (p<0.001) compared to primary tumor cells for each tumor type, along with the 
characteristic difference of ANV proliferation increased over MMC. The growth of mMMC 
shown in Figure 1D exhibited a small, rounded shape growing in mounds upward instead of the 
more cubical primary MMC growing as a monolayer, radiating outward. The growth of mANV 
retained a spindled basal-like mesenchymal phenotype. The overall morphology of mMMC and  
mANV following metastasis were similar to primary MMC and ANV tumor, respectively. 
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CD44+CD24-/low stem-like phenotype was established simultaneously with enhanced neu-
expression in mMMC during lung metastasis  
 
 Since relapsed ANV had characteristics of stem-like cells (7), we sought to determine 
whether establishment of primary tumor cells in the lung might result in the acquisition of a 
stem-like phenotype in MMC. As shown in Figure 2, mMMC acquired a stem-like phenotype in 
the lung by showing loss of CD24 expression (from 89.4% in MMC to 9.09% in mMMC) 
despite a universal upregulation of neu-protein (from 8.53% in CD24- MMC to 98.1% in CD24- 
mMMC; from 77.7% in CD24+ MMC to 99.3% in CD24+ mMMC). Retention of neu 
expression during CD24 loss suggests that loss of CD24 in mMMC was not merely due to the 
selection of CD24- phenotype from within the heterogeneous MMC population. Primary ANV 
(CD44+CD24-, 73.8%) and mANV (CD44+CD24-, 79.5%) exhibited a similar phenotype upon 
comparison indicating a stable lack of neu expression and stem-like metastatic phenotype.  
 
The invasive capacity of ANV remains stable following metastasis  
 
 In order to address the metastatic potential of mammary tumor cells, invasiveness was 
considered for MMC and ANV prior to and directly following metastasis. Boyden chamber 
invasion assay through Matrigel indicated positive invasion for mANV and ANV (Figure 3B & 
3C) while mMMC and MMC exhibited no invasion (Figure 3A & 3C). For comparison of cells 
before and after metastasis, ANV invasiveness remained stable following metastatic cascade 
while MMC exhibited poor or very low invasiveness without effect from metastasis. Positive 
invasion (Figure 3D) was evaluated by toluidine blue staining of cells that had successfully  
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broken down the Matrigel layer and migrated through 0.8 µm pores to the opposite side of the 
Boyden chamber during 48-hour growth. As this assay only tests for the breakdown of Type I/IV 
collagen present in basal membranes followed by successful migration, it is not considered 
representative of all forms of invasion, but merely just single-cell invasive means instead of 
collective or extracellular-mediated (macrophage or fibroblast) methods (62). 
 
MDSC levels were minimal in FVBN202 mice bearing lung metastatic mMMC or mANV tumor 
 
 Since tumor-derived soluble factors raise MDSC levels in vivo (48), we investigated 
whether mMMC or mANV may also increase splenic MDSC trafficking. MDSC levels were not 
increased in experimental metastatic mice (Figures 4A). The MDSC levels in mANV (9.3%) or 
mMMC (21.2%; n=3) experimental metastatic mice (Figure 4B) were lower than previously 
reported in mice challenged with MMC primary tumor (45). Splenomegaly was not observed in 
experimental metastatic mice, further supporting a drop in MDSC levels (Figure 4C).  
 
Tumor-reactive splenocytes can be expanded and reprogrammed from FVBN202 mice bearing 
lung metastatic mMMC or mANV 
 
 In order to address the use of B/I + γ-c cytokines in the expansion of metastatic tumor-
sensitized lymphocytes, splenocyte expansion efficiency and tumor-specific IFN-γ production 
were assessed for the experimental metastasis model (Figure 5). One day after B/I + IL-2 
treatment, a sharp drop was observed in the number of splenocytes from mMMC- sensitized 
(p=0.022) and mANV-sensitized mice (p=0.013), as previously seen by our group during  
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activation and reprogramming to indicate only tumor-antigen-primed cells were expanded (46). 
Splenocytes were successfully expanded on average from mMMC-sensitized mice (2.2-fold 
expansion by day 6) and mANV-sensitized mice (2.1-fold expansion by day 6) using B/I + γ-c 
cytokines over 6-7 days (Figure 5A & B, left upper panels). A 6-7 day culture of splenocytes 
with common γ-chain cytokines resulted in the notable expansion of splenocytes from mMMC-
sensitized (p=0.017) and mANV-sensitized mice (p=0.008). A moderate expansion of CD8+ and 
CD4+ T cells was observed in Figure 5A & B (upper right and lower panels) by exhibiting a 1.5- 
to 4-fold expansion, similar to previous results of ex vivo expansion of primary tumor-reactive 
splenocytes (46). Average CD8+ T cells increased overall during 6-7 day expansion from 
mMMC-sensitized (8.12% (D0) vs. 34.4% (D6); p=0.036) or mANV-sensitized mice (14.01% 
(D0) vs. 36.1% (D6-7)). Despite fluctuation following B/I + IL-2 from day 0 to day 1, average 
CD4+ T cells also increased overall during 6-7 day expansion from either mMMC-sensitized 
(32.2% (D0) vs. 48.8% (D6-7)) or mANV-sensitized mice (25.7% (D0) vs. 41.4% (D6-7); 
p=0.006). The specific variation shown by error bars (SEM) between mANV-sensitized mice 
(n=2) for average CD8+ or CD4+ T cells was observed simultaneously with an uncommon 
viability fluctuation in one mouse, from 95% viability at day 0 to 34% viability at day 1 
rebounding to 92% by day 7. Splenocytes expanded from mMMC-sensitized mice also showed 
IFN-γ production in Figure 5C against MMC and ANV tumors (average, 2279 pg/mL and 2176 
pg/mL, respectively). By comparison, expanded splenocytes from mANV-sensitized mice 
showed less IFN-γ production in Figure 5D against ANV and MMC tumors (average, 494 pg/mL 
and 964 pg/mL, respectively). IFN-γ production of splenocytes was positively indicated in 
response to tumor co-culture from both, mMMC- and mANV-sensitized mice but sample 
variation at this early time in the pilot study (n=2, mMMC-sensitized; n=3, mANV-sensitized  
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mice - for cross-reactivity against MMC, n=2) precluded any claims of significance being drawn. 
 Phenotype analysis of expanded splenocytes over 6-7 days revealed the efficiency of 
reprogramming anti-tumor immune cells from experimental metastatic mice (Figures 6-8). 
Figure 6 depicts a notable reduction of CD62L+ T cells (including CD44-CD62L+ naïve T cells 
(TN), CD44+CD62L+(low) effector memory T cells (TEM) and CD44+CD62L+(high) central 
memory T cells (TCM)) along with the enhancement of CD44+CD62L- effector T cells (TE) 
following B/I + IL-2 treatment on day 0 to day 1, supporting successful T cell reprogramming. A 
general downregulation of CD62L expression from 81.9% on day 0 to 69.7% on day 1 was seen 
in Figure 6A (lower left panel) in average mMMC-sensitized mice (p=0.00006). CD62L 
downregulation was absent from average mANV-sensitized CD8+ T cells in Figure 6B, but they 
exhibited a similar specific trend of reduction of average CD8+ TN cells (lower right panel) from 
19.9% on day 0 to 1.42% on day 1. CD62L downregulation was also observed in Figure 6C in 
average mMMC-sensitized CD4+ T cells from 75.9% at day 0 to 20.9% at day 1 (p=0.006). 
CD4+ T cells from mANV-sensitized mice exhibited a similar trend of CD62L downregulation 
from 79.8% on day 0 to 35.4% day 1 (n.s.) in Figure 6D despite a high level of sampling 
variation, supported by a notable reduction of CD4+ TN cells (16.1% to 4.96%; p=0.033). Also, 
average CD8+ TE cells increased from day 0 to day 1 in Figure 6A from mMMC-sensitized mice 
(9.98% to 15.9%; p=0.031) and in Figure 6B from mANV-sensitized mice (40% to 50.9%; n.s.). 
An increase in average CD4+ TE cells was similarly observed from day 0 to day 1 in Figure 6C 
in mMMC-sensitized mice (20.3% to 69.3%; p=0.009) and in Figure 6D from mANV-sensitized 
mice (18.2% to 60.9%; n.s.). Further, a strong reprogramming and phenotypic differentiation by 
day 6 towards a central memory T cell (TCM) phenotype in mMMC-sensitized and mANV- 
sensitized mice was exhibited in Figure 6, concurrent with a noticeable drop in effector memory 
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T cells (TEM) and naïve T cells (TN), as previously seen (46). Average CD8+ TCM cells were 
expanded by day 6 from baseline from both, mMMC-sensitized (Figure 6A, 59%; p=0.001) and 
mANV-sensitized mice (Figure 6B, 74.8%; n.s.). Average CD4+ TCM cells were also expanded 
by day 6 from baseline from both, mMMC-sensitized (Figure 6C, 75%; p=0.001) and mANV-
sensitized mice (Figure 6D, 69.8%; p=0.036).  
In order to evaluate the splenocyte activation status in response to 6-7 day expansion, 
CD25 and CD69 expression levels were investigated. The activation events induced by B/I+IL-2 
were seen on day 1 for CD8+ and CD4+ T cells by CD25 expression (2- to 10-fold increases in 
average CD25+ cells) and sustained until day 6 as shown in Figure 7 (A-D). CD25+ activation 
events were clearly discerned from mMMC-sensitized mice in Figure 7A in average 
CD8+CD25+ T cells from 14.2% on day 0 increasing to 82.3% on day 1 (p=0.008) persisting to 
day 6 (66.3%; p=0.007, D0 vs. D6). Average CD4+CD25+ T cells from mMMC-sensitized mice 
in Figure 7B also increased from 7.39% on day 0 to 80.1% on day 1 (p=0.002) persisting to day 
6 (85.6%; p=0.001). By comparison, activation trends were also discerned from mANV-
sensitized mice in Figure 7C in average CD8+CD25+ T cells increasing from 24.6% on day 0 to 
49.7% on day 1, stable to day 6-7 (48.7%). The aforementioned technical issue of fluctuating 
viability at day 1 in splenocytes from one mANV-sensitized mouse may be considered the cause 
of the difference observed between the high values of representative data shown in the left panel 
of Figure 7C for CD8+CD25+ T cells and the lower averaged data on the right with large error 
bars to indicate this notable variation, presumably also affecting comparative statistical analysis. 
Average CD4+CD25+ T cells from mANV-sensitized mice also comparably increased in Figure 
7D from 9.78% on day 0 to 44.6% on day 1, increasing to day 6-7 (91.6%; p=0.009). Early 
activation, as indicated by CD69 expression, was clearly seen in Figure 7 (E-H) at day 1 with a 
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2- to 7-fold increase in average CD69+ cells. B/I + IL-2 induced CD69 expression on average in 
mMMC-sensitized CD8+ T cells (Figure 7E, 87.5% (D1); p=0.009) and CD4+ T cells (Figure 
7F, 90.9% (D1)), which subsided by day 6 as expected. Expression of CD69 was not sharply 
detected until day 6-7 in CD8+ T cells from mANV-sensitized mice as a 5-fold increase in 
average CD69+ cells (Figure 7G, 87.9%), while only minimal activation was detected in CD4+ T 
cells (Figure 7H, 32.8%) during expansion.  
Previously, we have shown that anti-tumor efficacy of reprogrammed T cells in vivo 
depended on the reprogramming and presence of activated NKT cells and NK cells (46). Tumor 
bearing mMMC or mANV animals were analyzed for the presence of non-T cells among the 
reprogrammed immune cells over the course of 6-7 day expansion (Figure 8). Notably, the larger 
proportion of NK cells found at day 0 and day 1, shifted to predominantly expanded NKT cells at 
day 6 (p=0.013) in mMMC-sensitized mice as shown in Figure 8A. By comparison, mANV-
sensitized mice exhibited a similar shift of NK to NKT cells by day 6-7 in Figure 8B, while there 
were more NKT cells at the initial observation. Evidence of activation from day 0 to day 1 in 
non-T cell populations was shown in Figure 8C for splenocytes derived from mMMC-sensitized 
mice. NKT cells from mMMC-sensitized mice were significantly activated at day 1 with 60.7% 
expressing CD25 (p=0.007) and 63.5% of NK cells were activated expressing CD25 (p=0.022) at 
day 1 in response to B/I + IL-2. Upon closer inspection, non-T cells from mANV-sensitized mice 
were less responsive to B/I + IL-2 activation at day 1 (NKT25+, 16%; NK25+, 1.16%) in Figure 
8D when compared to mMMC-sensitized non-T cells. Overall ex vivo expansion of responsive 
immune cells by day 6 from mMMC-sensitized mice revealed a strong presence of activated 
NKT cells on average (90% (D6); p=0.004) and a minor population of activated NK cells on 
average (40.9% (D6); p=0.043) upon reprogramming. Also, splenocytes from mANV-sensitized 
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mice exhibited a similar responsive expansion of activated NKT (85.2%) and NK cells (34.5%) 
by day 6-7. 
 
Tumor-specific cytotoxicity was initiated by reprogrammed T cells from mMMC-sensitized and 
mANV-sensitized mice 
 
 In order to determine the effectiveness of expanded splenocytes at tumor-specific killing, 
cytotoxicity assays were performed with reprogrammed immune cells from mMMC-sensitized or 
mANV-sensitized mice against each tumor-type of interest in vitro. Reprogrammed T cells from 
mMMC-sensitized mice in Figure 9A (left panel) showed some specific cytotoxicity on average 
against mMMC tumor (32.45% viability compared to tumor alone, 46.5%) as well as significant 
cross-reactivity to MMC tumor (40.65% viability compared to 59.1%), ANV tumor (54% 
viability compared to 82.8%) and mANV tumor (76.3% viability compared to 83.5%). The 
average normalized viability of tumors + T cells from mMMC-sensitized mice compared to each 
type of tumor was plotted (right panel) for cytotoxic effect, revealing notable cross-reactivity 
against MMC (p=0.036), ANV (p=0.041) and mANV (p=0.035). There was some variation 
present shown by standard error bars between mMMC + T cell samples, accounting for the lack 
of statistical significance despite a similar decreasing trend in tumor viability compared to other 
tumors treated with reprogrammed T cells. Also, the small sample size (n=2) undertaken for the 
pilot study to show cytotoxic tumor killing limits the power of the assay for drawing conclusions. 
For indirect study of variations in tumor-killing functions of reprogrammed cells that may be 
associated with activation-induced T cell death (AICD) resulting from tumor co-culture, viability 
of CD3+ T cells was evaluated in the presence or absence of the tumor cells in vitro. Activation- 
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induced cell death from mMMC-sensitized mice towards mMMC, MMC or ANV in Figure 9B 
was within 8% of control. Apart from AICD due to co-culture with mANV (p=0.028), any 
average reported change from control in Figure 9B was most likely due to assay variation. 
By comparison, reprogrammed T cells from a mANV-sensitized mouse in Figure 10A 
(left panel) showed specific cytotoxicity against mANV (43.8% viability compared to tumor 
alone, 87.8%) and cross-reactivity against ANV (46.1% viability compared to 88.3%) as well as 
against neu+ MMC (40.7% viability compared to 48.3%). Normalized viability plotted of tumors 
+ T cells from one mANV-sensitized mouse had a cytotoxic effect of up to 50% compared to 
each type of tumor in Figure 10A (right panel). The cytotoxic effect observed from mANV-
sensitized T cells was greater than that observed from mMMC-sensitized T cells, which conflicts 
with the immunogenicity indicated by earlier IFN-γ production in response to mMMC tumor. 
Different gating strategies were employed for comparison during optimization in assessing the 
cytotoxic tumor-killing function of the reprogrammed T cells against MMC (CD3- cells vs. neu+ 
cells). When gating on intact neu+ cells, a difference in percent tumor viability (~10%) was 
noted between gating on CD3- cells, but the neu+ gating strategy was preferred for overall cell 
specificity for MMC or mMMC tumor cells. Also, all values of T cell AICD against the three 
tumors plotted in Figure 10B (right panel) were less than 9% difference from control, likely as 
assay variation.  
 
Unlike stable mANV, stem-like mMMC exhibited reversible neu-expression upon s.c. challenge 
due to tumor site change 
 
In order to determine whether any phenotypic changes in mMMC or mANV during lung 






	   32	  
metastasis remain stable or may be reversible upon the influence of tumor site, FVBN202 mice 
were inoculated by subcutaneous (s.c.) challenge with mMMC and/or mANV in the groin region. 
The purpose of simultaneous contralateral challenge with mMMC and mANV highlighted either 
if there were phenotypic changes exerted on the tumor cells by altering the tumor site, 
confirming TME crosstalk if the changes were noted in both tumors, or if the tumors were 
exerting phenotypic changes on each other, confirmed by subsequent separate tumor challenges 
as necessary. As shown in Figure 11A, mMMC retained a stem-like phenotype (CD44+CD24-, 
73.4%) indicating a stable change while exhibiting a novel loss of neu-expression (neu+, 32.4-
51.5% s.c. instead of 98.1-99.3 i.v.) in response to tumor microenvironment (TME) change in a 
tissue-specific manner. A stable expression of the neu-protein and stem-like phenotypic markers 
was exhibited by mANV upon s.c. challenge, indicating phenotypic stability in different tumor 
microenvironments. These data suggest that relapsing ANV was more stable than primary MMC 
upon changes in the TME during and following metastasis. Compared to MMC primary cells, 
neu+ metastatic tumor cells are irrevocably changed in stem-ness by susceptibility to tissue-
specific TME influence. 
 
Tumorigenicity of metastatic tumor cell lines was increased in vivo  
 
In order to determine the tumorigenicity of mMMC and mANV by comparison to 
primary cells, FVBN202 mice were challenged s.c. with mMMC, mANV and MMC. 
Surprisingly, tumorigenicity of the metastatic tumor cells upon s.c. injection of mMMC and 
mANV on contralateral sides of the same mouse (Figure 11B, left panel) or separately inoculated 
in different mice (Figure 11B, right panel) conflicts with the earlier proliferation data in vitro  
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(Figure 1C). Animals inoculated with mMMC showed a greater tumor burden than those 
inoculated with mANV tumor cells at 16 days after challenge (left panel: 750 mm3 vs. 150 mm3; 
right panel: 1150 mm3 vs. 100 mm3, respectively). These data are in agreement with the earlier 
significant differences in time for lung metastatic disease affecting moribundity to develop in 
mMMC-bearing mice (23.6 days) versus mANV-bearing mice (28.5 days), requiring sacrifice 
(Figure 1B). Further study with a more advanced invasion model would be required to determine 
whether the lower tumorigenicity of mANV may be because of a higher invasiveness in vivo that 
results in rapid tumor migration to distant sites parallel to primary tumor growth that would be 
poorly assessed by the current assays available for study, as previously noted above.  
 
Tumor-reactive splenocyte expansion and reprogramming efficacy was unaffected by change in 
mMMC or mANV tumor growth site while IFN-γ production and MDSC levels were reduced 
 
Since our previous findings have shown mMMC to be susceptible to TME influence 
upon s.c. challenge (above), the effect of changing tumor site following metastasis was briefly 
investigated for any downstream effects to the elicited anti-tumor immune response. Despite 
strong expansion (4.5-fold, day 5-6) from a mouse s.c. challenged with mMMC and mANV on 
contralateral sides (Figure 11C), a weak level of immunogenicity was indicated by IFN-γ 
production (average, ≤300 pg/mL) from reprogrammed splenocytes co-cultured with tumor 
(Figure 11D) when compared to earlier results (Figure 5A-D). A 5-fold expansion of CD8+ 
lymphocytes was noted by day 6 (40.3%) from day 0 (8.12%) shown in Figure 11E. Following a 
change in tumor localization site of mMMC or mANV, MDSC levels in FVBN202 mice s.c. 
challenged with mMMC and/or mANV (Figure 12) were intermediate compared to a mouse s.c.  
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challenged with control MMC and the previously described lung metastatic mice (Figure 4A & 
4B), indicating tissue-specific effects on MDSC trafficking regardless of tumor burden.  
In order to determine whether localization of mMMC or mANV in the groin region s.c. 
may also result in a different pattern of responses from immune cells to ex vivo reprogramming, 
splenocytes from a FVBN202 mouse s.c. challenged contralaterally with mANV and mMMC 
were examined.	  Similar trends of reprogramming as reported above in the reduction of CD62L+ 
T cells (including CD44-CD62L+ naïve T cells (TN)) along with the enhancement of 
CD44+CD62L- effector T cells (TE) following B/I + IL-2 treatment were observed from day 0 to 
day 1 in Figure 13A. Reprogramming towards a TCM phenotype was still seen from day 0 to day 
6 in CD8+ T cells (4.3% vs. 64.4%) or CD4+ T cells (2.6% vs. 59.6%) despite tumor site change 
(Figure 13A). The memory lymphocyte phenotype in the s.c. contralaterally-challenged mANV 
and mMMC mouse of a lower TEM presence and increased TN presence was opposite the MMC 
control mouse (shown at right of figure) measured at baseline (D0). A similar responsive 
activation status at day 1 was noted in the mANV and mMMC s.c. contralaterally-challenged 
mouse (Figure 13B) by CD8+CD25+ (9-fold) or CD4+CD25+ expression (21-fold) and 
CD8+CD69+ (4.5-fold) or CD4+CD69+ expression (6.5-fold) as previously discussed for 
experimental metastatic mice (Figure 7A-H). Notably, a robust activated NK cell presence was 
found in Figure 13C among the reprogrammed splenocytes of the s.c. contralaterally-challenged 
mANV and mMMC mouse by day 6 of expansion (NK, 11 or 13.7% by different gating 
strategies) after changes in tumor site, when compared to the earlier described metastatic mice 
(Figure 8). However, a similar activated NKT cell presence at day 6 (NKT25+ 94.9%) was found 
in the s.c. contralaterally-challenged mANV and mMMC mouse following expansion. The 
expanded activated lymphocyte and non-T cell populations from the s.c. contralaterally-  
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challenged mANV and mMMC mouse in comparison to the MMC control mouse (shown at right 
of figures) confirmed a relatively normal baseline immune response to the established metastatic 
tumor cells inoculated in a different tumor site.  
 
Tumor-specific and cross-reactive cytotoxicity was initiated by reprogrammed T cells despite 
TME influences following s.c. contralateral challenge with mMMC and mANV 
 
In order to determine the efficacy of reprogrammed splenocytes at tumor-specific killing 
from a FVBN202 mouse s.c. challenged contralaterally with mANV and mMMC, tumor-specific 
and cross-reactive cytotoxicity was assessed from co-culture of expanded splenocytes with the  
four tumors of interest. Reprogrammed T cells from the mANV and mMMC s.c. mouse show 
specific and cross-reactive cytotoxicity against the tumors in vitro (Figure 14A). A strong 
specific cytotoxic effect was exhibited by viability drop from 45.2% to 6.14% when comparing 
mMMC tumor alone to mMMC + T cells, respectively. Figure 14A also depicted the weakest 
cytotoxic effect by a viability drop from 80.1% to 53.3% when comparing mANV tumor alone to 
mANV + T cells, respectively. There was evidence of a cross-reactive cytotoxic effect from 
reprogrammed T cells on ANV (31.3% viability compared to tumor alone, 73.3%) and MMC 
(15.5% viability compared to tumor alone, 51.9%). Normalized viability data showed the 
previous spectral trends of specific and cross-reactive cytotoxicity upon T cell co-culture with 
the respective tumors of interest when compared to tumor alone. Tumor viability of mMMC by 
trypan blue exclusion was regularly higher than 80% following 48-hour growth, suggesting cell 
sensitivity to the processes/reagents of the Annexin/PI viability assay from repeated studies, 
hence the inclusion of data below 50% viability. The mMMC cells actively formed into clumps  
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in suspension that were nearly impossible to disaggregate effectively through repeat pipetting or 
gentle vortexing without employing trypsin or EDTA. The clumped mMMC cells may have 
become sheared during flow analysis affecting the previous viability assay outcomes, as the 
sheath was designed for the passage of single cells. Further, AICD was again indirectly studied 
in search of variations to the tumor-killing functions of reprogrammed splenocytes co-cultured 
with tumor by comparison among the four tumor types of interest. AICD data (Figure 14B) 
suggested that the lowest amount of CD3+ T cell engagement (inversely, the highest viability) 
with tumor was seen with mANV (34.6%) consistent with viability loss data and the most AICD 






































The efficacy of ex vivo expansion and reprogramming of tumor-reactive immune cells 
from mMMC- and/or mANV-sensitized mice was determined along with any phenotypic 
changes in tumors due to metastasis or TME influences (Table 1). Two cell lines were 
established following experimental metastasis with either MMC or ANV in FVBN202 mice. 
mMMC exhibited a higher macrometastatic tumor-initiating capability than mANV in the lungs 
while mANV exhibited higher proliferation in vitro than mMMC. Each metastatic cell line, 
mMMC or mANV, exhibited higher proliferation rates than their primary tumor counterparts, 
MMC or ANV, respectively, despite showing similar overall morphology. CD44+CD24-/low 
stem-like phenotype was acquired with enhanced neu-expression in mMMC during lung 
metastasis while stem-like mANV exhibited a stable lack of neu-expression. ANV invasiveness 
remained stable following metastatic cascade while MMC exhibited poor or very low 
invasiveness without effect from metastasis. MDSC levels were not increased in experimental 
metastatic mice nor was splenomegaly observed. Splenocytes were successfully expanded on 
average from mMMC-sensitized mice and/or mANV-sensitized mice using B/I + γ-c cytokines 
over 6-7 days. CD8+ and CD4+ splenocytes were expanded in mMMC- or mANV-sensitized 
mice. The 6-7 day expansions resulted in tumor-specific and cross-reactive IFN-γ production 
from reprogrammed splenocytes in mMMC- or mANV-sensitized mice. Ex vivo expansion and 
reprogramming was successful due to the downregulation of CD62L expression simultaneously 
with an increase in effector T cells at day 1, signs of responsive activation by CD25 or CD69  
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Table 1.   Summary of key findings 
 
• Experimental lung metastasis resulted in the establishment of two cell lines, mMMC and mANV 
• mMMC exhibited a higher macrometastatic tumor-initiating capability than mANV in the lungs 
• mANV exhibited a higher proliferative rate than mMMC in vitro 
• Metastasis directly increased the proliferative rates of mMMC and mANV over MMC or ANV in vitro 
• Metastasis induced CD44+CD24-/low stemness phenotype with enhanced neu-expression in mMMC  
• mANV retained a stable stemness phenotype and lack of neu expression during metastasis 
• Metastasis failed to effect the invasiveness pattern of invasive ANV or non-invasive MMC in vitro 
• MDSC levels were not increased in lung metastatic mice bearing mMMC or mANV 
• CD8+ and CD4+ splenocyte expansion was successful from lung metastatic mice using B/I + γ-c cytokines 
• Tumor-specific and cross-reactive IFN-γ production was observed in mMMC- or mANV-sensitized mice 
• Successful reprogramming of splenocytes was observed from mMMC- or mANV-sensitized mice 
• Responsive activation was indicated by CD25 or CD69 expression in mMMC- or mANV-sensitized splenocytes 
• Central memory T cells and activated NK/NKT cells were differentiated from mMMC- or mANV-sensitized mice 
• Tumor-specific and cross-reactive cytotoxicity was observed from mMMC- or mANV-sensitized splenocytes  
• Tumor site change effected a reversal in neu-expression without an effect on stemness in mMMC  
• Tumorigenicity was increased for mMMC over mANV in vivo upon tumor site change 
• Tumor-reactive splenocyte expansion and reprogramming was unaffected by mMMC and mANV tumor site change 
• Tumor site change of mMMC and mANV reduced IFN-γ production and MDSC levels compared to primary tumors 
• Tumor site change of mMMC and mANV did not alter the initiation of a positive anti-tumor cytotoxic response  
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expression at day 1 and the phenotypic differentiation of central memory T cells with activated 
NK/NKT cells by day 6 from mMMC- or mANV-sensitized mice. Tumor-specific and cross-
reactive cytotoxicity was observed from splenocytes expanded from mMMC- or mANV-
sensitized mice. The contributions of tumor site on metastatic disease were determined in mice 
s.c. challenged with mANV, mMMC or both contralaterally. Neu-expression was flexibly 
reversed in mMMC s.c. challenged mouse while a stable phenotype was observed in mANV 
(lack of neu) or MMC control (neu-overexpressing) s.c. challenged mice. Tumorigenicity was 
increased for mMMC over mANV in vivo in mice s.c. challenged with mANV, mMMC or both 
contralaterally. Further, tumor-reactive splenocyte expansion and reprogramming efficacy was 
unaffected by change in mMMC and mANV tumor growth site while IFN-γ production and 
MDSC levels were reduced, compared to primary tumors. Finally, tumor-specific and cross-
reactive cytotoxicity was initiated by reprogrammed immune cells despite TME influences 
following s.c. contralateral challenge with mMMC and mANV. 
mMMC and mANV were studied following experimental metastasis by tail-vein injection 
for their phenotypic changes in disease progression, growth character, stemness changes, 
proliferation rate, invasiveness and suppressive cell recruitment. By comparison to their primary 
counterparts, the metastatic cells revealed some very interesting phenotypic changes that 
correlate with tissue-tropism and common metastasis-induced mesenchymal or epithelial 
changes (11). Macrometastatic disease formed in the lungs of mMMC-sensitized mice faster than 
mANV-sensitized mice on average. Pulmonary metastasis gave rise to established cell lines, 
mMMC and mANV, that proliferated faster in vitro compared to the original MMC and ANV. 
Our group previously showed a higher proliferative capacity in ANV compared to MMC, which 
was conserved by our experiments in vitro following experimental metastasis (53). The enhanced 
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level of growth factors and compatibility of the growth surface in vitro have been implicated in 
differences in cellular proliferative capacity, but further molecular studies would be required to 
remove speculation in differences between the two differing tumor microenvironments. 
Growth character was similar following metastasis for mMMC and mANV compared to 
their primary tumor counterparts, yet mMMC showed a high degree of aggregation when in 
suspension that required extensive chemical or mechanical disaggregation. This alteration to cell 
adhesion is consistent with reductions in gene expression responsible for tight junctions or 
intercellular adhesion (e.g., E-cadherin) following the metastatic cascade as previously reported 
in mammary carcinoma  (23, 63-66). The suggested changes in tumor aggregation have been 
linked with changes in tumor initiation and self-renewal associated with the epithelial to 
mesenchymal transition (EMT) portion of the metastatic cascade when tested for mammosphere 
formation  (12, 67-69). ANV and mANV exhibited a spindle-like morphology characteristic of 
mesenchymal cells that in this instance may have undergone EMT during initial relapse  (12, 23, 
24, 67-69). As expected, mANV was invasive and migratory through Matrigel following 
metastasis, similar to ANV, as previously shown by pathology (7). However, mMMC was not 
invasive following metastatic cascade like MMC, showing no tumor cell-derived change in 
invasion. Recently, tumor dissemination has been explored from metastatic and non-metastatic 
breast carcinomas influenced by tumor-associated macrophages (TAMs) or neoangiogenesis as 
potent inducers of metastasis  (27, 70, 71). These prospects of metastatic initiation via TAMs and 
angiogenic means are probable in our current experimental metastatic model due to the 
previously reported production of MCP-1/CCL2 (monocyte/macrophage chemoattractant) and 
VEGF (angiogenic soluble factor) in mouse mammary carcinoma (48). 
	   45	  
 Previously the stem-like phenotype, CD44+CD24-/low, was characterized in mammary 
carcinoma to show an increased tumorigenicity (14, 15), but it has also been associated with 
increases in potential tumor initiation and drug/radiation resistance (16-18). Upon lung 
metastasis, a stem-like phenotype of CD44+CD24- was induced in mMMC from the original 
CD44+CD24+ MMC, while the stemness of primary ANV was retained in mANV. Neu-protein 
expression increased following metastasis with MMC, but no change was seen with relapsing 
ANV, indicating phenotypic stability. The simultaneous loss of CD24 expression and 
upregulation of neu expression indicates flexibility in mMMC to the metastatic process that is 
not solely selection of surviving clones which may be due to epigenetic modifications during 
metastasis  (72). The fluctuation in neu expression has previously been evaluated in response to 
various treatments by our group (53). However, this was the first instance that conclusively 
showed two changes in the original MMC population, opposite in trend yet similar in the nature 
of suggested epigenetic modification. If the trend were Darwinian selection, clonal enrichment 
would be selected for during metastasis from the CD24- population with low neu expression, 
which was not the case. Bisulfite sequencing would be required to confirm any changes to 
methylation states, but based on previous work by our group, the stability of ANV is most likely 
due to the higher degree of methylation (gene silencing) present when compared to MMC at the 
MMTV promoter (53). The hypomethylation of MMC previously allowed for increased 
expression of neu, but this lower level of genetic stability could also lead to the epigenetic loss of 
CD24 during metastasis or relapse. Many groups have observed epigenetic changes during 
cancer progression, including an induced state of hypermethylation of multiple proximal 
promoters to stemness-related genes, drastically altering the phenotypes of adult human cancers 
(72). The proposed epigenetic changes in response to the TME may be the means for initial 
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relapse of ANV to an alternate site with less tissue-specific neu expression, affecting its growth 
pattern towards temporary dormancy while experiencing immune pressure to survive. Previous 
connections to immune regulation of breast cancer cells showed changes in HER2/neu+ 
expression as a form of immune escape (23, 53) that could be flexible in response to tissue-
specific HER2/neu+ expression when involved in crosstalk with various tissues, including the 
compatible HER2/neu+ lungs during metastasis (73). Lung tissue also produces tumor-
promoting TGF-β1 and periostin, while other cancers have been associated with pulmonary 
metastases due to the welcoming VEGFR1+ endothelial microenvironment and MMP9 activity 
from TAMs (71, 74, 75). This idea of tissue compatibility during metastasis and survival 
signaling at the secondary site(s), instead of required growth factors, may be key to 
understanding the tendency toward dormancy of disseminated cells allowing for disease 
recurrence 25 years later (27, 28, 75). 
Our group has previously linked the release of tumor-derived soluble factors to a rise in 
circulating MDSC levels (48). These immunosuppressive cells have previously been linked to 
tumor evasion and ultimate escape (45). Reprogrammed immune cells have been effective at 
overcoming MDSC suppression (due to NK/NKT cells) in prophylactic adoptive transfer against 
primary MMC (46). Amidst mixed reports on suppression models present in metastatic breast 
cancer (40, 76, 77), the MDSC involvement in our metastasis model was determined. Previously, 
our group determined that regulatory T cells were not present following B/I + γ-c cytokine 
expansion based on suppression functions measured in vitro (58), while MDSC suppression has 
been characterized in our FVBN202 mouse model (45, 48). MDSC levels were not increased in 
mice bearing lung metastases, suggesting an altered phenotype of soluble factor (GM-CSF) 
release from mMMC or mANV as a result of metastatic cascade (48). 
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Splenocytes from mMMC-sensitized or mANV-sensitized mice were successfully 
expanded and shown to be tumor-reactive by IFN-γ production following a characteristic drop in 
numbers from reprogramming with B/I + γ-c. The successful expansion of tumor-reactive 
splenocytes from mMMC-sensitized or mANV-sensitized mice was evident from the CD8+ and 
CD4+ T cell increases over 6-7 day expansion, as seen before by our group (46). The potential 
technical issue for one mouse, indicated by an unexpected viability fluctuation and variation 
shown by standard error, explains the lack of statistical significance at this early stage in the pilot 
study despite the observed increasing trends of average CD8+ or CD4+ T cells from mANV-
sensitized mice during expansion. It is likely the increasing trends would be reinforced upon 
further repeats, as supported by the relatively similar IFN-γ production among mMMC- or 
mANV-sensitized mice. The cross-reactive nature of IFN-γ production from expanded mMMC- 
or mANV-sensitized immune cells suggests the greater immunogenicity associated with the neu+ 
MMC cells when compared with the antigen-negative variant (ANV). Interestingly, despite the 
antigen difference, mice sensitized with opposite tumor cell types retained reactivity against both 
tumor types and in the case of mANV-sensitized mice, produced a stronger IFN-γ response 
against opposite tumor, neu+ MMC. Again, with further repeats we would expect reinforced 
trends of tumor-specific and cross-reactive IFN-γ production following metastatic cascade as the 
study progresses. Notably, the nature of tumor-specific IFN-γ production along with cross-
reactivity against opposite tumors elicited during the anti-tumor immune response may have 
ramifications in enhanced immune cell access to circulating tumor cells during the metastatic 
cascade through the vasculature, but it also shows that certain cell epitope signatures may not be 
lost during neu-antigen loss under immune pressure when considering the effective priming of an 
anti-tumor response towards mMMC or mANV (26, 55, 78). 
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 Reprogramming with B/I + IL-2 resulted in the downregulation of CD62L expression, 
including the characteristic reduction of TN cells, along with the strong increase in TE cells 
following treatment in either mMMC- or mANV-sensitized mice. Further evidence of successful 
reprogramming was shown in the activation events indicated by CD25 or CD69 expression in 
mMMC-sensitized mice and later seen in mANV-sensitized mice. Phenotypic differentiation of 
splenocytes into TCM cells following expansion was observed in all lung metastatic mice. 
Previous work by our group has shown that AIT performed with the separate T cell subtypes 
suggests a synergy for effective protection against tumor, lost when subtypes were separately 
tested (46), but the TCM cells have been reported to confer the greatest long-term anti-tumor 
protection (79-81). Further, the NK/NKT cell populations were investigated for their 
contribution to the anti-tumor immune response and to overcoming immunosuppression (46). An 
increase in NK cells was seen in response to B/I, but the population had decreased by the end of 
expansion, while a strong increase in NKT cells was observed throughout expansion. Activation 
was indicated in both NK and NKT cells, with emphasis on the latter. The importance of 
activated NKT cells during an effective anti-tumor response has recently been shown to be an 
NKG2D-dependent interaction (manuscript submitted). Apart from a general reduction in 
effector, effector memory, and NK cells following expansion, the trends in successful 
reprogramming and phenotypic differentiation examined in our experimental metastatic model 
follow our earlier work with MMC injected s.c. in FVBN202 mice (46). 
Tumor-reactive splenocytes expanded from mMMC-sensitized and mANV-sensitized 
mice caused specific and cross-reactive cytotoxicity upon 48-hour co-culture with the tumors of 
interest. Tumor-specific and cross-reactive cytotoxicity in mMMC-sensitized mice was elicited 
roughly equally against mMMC (n.s.), MMC, and ANV, while a weaker significant cross-
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reactive cytotoxicity was elicited against mANV tumors. Specific cytotoxicity in a mANV-
sensitized mouse was elicited against mANV and ANV while less cross-reactive cytotoxicity 
was elicited against MMC tumors. Specific and cross-reactive tumor cytotoxicity confirms the 
idea that ex vivo reprogrammed splenocytes from mMMC-sensitized and mANV-sensitized mice 
can effectively target and destroy tumor in vitro. Another immune evasive technique recently 
proposed is the Fas-counterattack where a tumor may display Fas-L to induce apoptosis in T 
lymphocyte populations similar to normal T cell population regulation  (82). Activation-induced 
cell death (AICD) was monitored for variations of reprogrammed cell activity during tumor co-
culture. The level of AICD present in both mMMC-sensitized and mANV-sensitized mice were 
similar to control, with any reported difference within a range of 9% viability away from the 
control. The only significant difference in AICD found in the reprogrammed cells was from 
mMMC-sensitized T cells co-cultured with mANV, but based on the tumor viability of mANV, 
it might simply have been a case of tumors outcompeting T cells for nutrients in vitro. These 
results indicate there is not an active immune evasive technique being employed by the tumor 
cells following metastasis because there were no associated changes to viability between tumor/ 
T cell co-cultures to indicate a Fas/FasL counterattack present in our cells. 
By changing the tumor site, the stability of the stem-like phenotype and neu expression 
found on mMMC and mANV could be investigated in response to tumor microenvironment 
changes. Following s.c. injection with mMMC, the stem-like phenotype was mostly retained 
while neu expression was downregulated in both, CD24- or CD24+ populations. After s.c. 
injection with mANV, the stem-like phenotype and neu expression was stable despite tumor site 
changes. By comparison to stable primary MMC cells injected s.c., mMMC cells were only 
stable for the stem-like phenotype but flexibly reversed in neu expression. The effects of the 
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metastatic cascade caused a stable change toward stemness in mMMC, but left mANV 
unchanged, possibly due to methylation differences as previously reported (53) which caused the 
susceptibility to change in mMMC. The dynamic process of metastasis caused more than just 
immune pressure as the neu expression change upon tumor site change could be explained. The 
pressure to survive in distant sites may be the trigger towards adopting a stem-like phenotype by 
epigenetic means within the same generation of cell growth due to crosstalk with the new TME 
following tissue-tropic metastatic homing and, recently proposed, autophagy (22). 
Tumorigenicity was determined upon s.c. injection of mMMC and mANV on 
contralateral sides, confirmed with subsequent separate challenges of the tumors. The tumor 
burden resulting from mMMC was greater than from mANV, along with a faster rate of 
development. The change in tumorigenicity conflicted with earlier proliferation data but the time 
to develop the tumors s.c. was consistent with the average time for development of lung 
metastatic disease that affects overall health (above). The change in mANV growth in vivo could 
be explained by a greater degree of invasiveness upon metastasis if the tumor rapidly migrated 
away from the s.c. site of challenge, according to the parallel metastasis model (8). Alternatively, 
a potentially higher degree of methylation could also limit the proliferative rate of mANV similar 
to the original relapse event for a certain amount of time before reactivation if induced by 
metastatic cascade, which would correlate with the induction of stemness at initial relapse (72). 
 The expansion of splenocytes from a mouse s.c. contralaterally-challenged with mMMC 
and mANV was stronger than lung metastatic mice challenged with mMMC or mANV, most 
likely due to altered immune cell types trafficking to the subcutaneous tumor site or increased 
immune cell access to prime a response against two tumors instead of single challenge with great 
proximity to draining lymph nodes during dendritic cell maturation. The IFN-γ response of 
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reprogrammed splenocytes to the tumors when s.c. contralaterally-challenged with mMMC and 
mANV was lower than the response from mMMC-sensitized or mANV-sensitized splenocytes 
from lung metastatic mice. Further, the MDSC trafficking in s.c. contralaterally-challenged mice 
with mMMC and/or mANV was intermediate compared to the lower levels in mMMC-sensitized 
or mANV-sensitized lung metastatic mice and the levels observed in mice s.c. challenged with 
primary MMC, regardless of tumor burden or time after challenge. This difference in MDSC 
trafficking is most likely due to an altered lower expression pattern of tumor-derived soluble 
factors, including GMCSF, following metastasis even with the tumor site changed back to our 
original s.c. model (48). 
Splenocytes were also phenotypically characterized from the mMMC-sensitized and 
mANV-sensitized s.c. contralaterally-challenged mouse for any contribution of change in tumor 
site on the immune response following metastasis. Similar trends were observed in the mMMC-
sensitized and mANV-sensitized s.c. contralateral-challenged mouse during reprogramming. A 
similar downregulation of CD62L expression (including naive T cells) and an enhancement of 
effector T cells was exhibited following B/I treatment. Also, a robust expansion of CD8+ 
lymphocytes was similarly seen here. A responsive activation was similarly seen by CD25 and 
CD69 expression following B/I in CD8+ or CD4+ lymphocytes. Surprisingly, a larger NK 
presence was noted upon s.c. challenge during expansion than with mMMC-sensitized or 
mANV-sensitized lung metastatic mice, similar to our previous work with subcutaneous 
challenge. This difference in NK cell proportion expanded may be a tissue specific change upon 
s.c. tumor challenge. A similar level of NKT cells was observed among the different challenges 
and the activation of non-T cells was relatively equivalent when comparing mMMC-sensitized or 
mANV-sensitized lung metastatic mice to the s.c. contralaterally-challenged mouse. When 
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comparing the s.c. contralaterally-challenged mouse to a mouse challenged s.c. with MMC 
control for baseline, the immune response was relatively normal upon dual tumor challenge with 
the only difference being a lower effector memory and increased naive cell presence in the 
contralateral mouse. 
In order to see if a tumor site change may affect the efficacy of reprogrammed 
splenocytes at tumor killing, cytotoxicity was assessed from co-culture of splenocytes from 
mMMC and mANV s.c. contralaterally-challenged mouse with the tumors of interest. A strong 
viability drop indicated specific and cross-reactive cytotoxicity against all four tumors with 
contralateral challenge s.c. A high degree of AICD was implied for T cells co-cultured with any 
of the four tumors that could confirm the expected high level of T cell engagement with tumor 
already described from the viability data, in addition to the strength of expansion indicated. 
However, the strong cytotoxic tumor killing indicated is inversely related to the IFN-γ levels 
reported from the contralaterally-challenged mouse. The previous difficulty with optimizing the 
cytotoxicity assay indicates the need for replicates to confirm any preliminary trends. Again, the 
level of AICD would indicate there is not an appreciable change in Fas/FasL expression as a 
form of immune evasion in the metastatic tumors since none of the T cell samples were 
significantly different than each other without a T cell control to be certain during assay 
optimization (82). 
Despite the losses in some tumor-reactive cell types, the results of substantial TCM cell 
and activated NKT cell expansion make a strong case for the application of adoptive cellular 
therapy (ACT) in metastatic or relapsed malignant disease. Our group previously showed 
effective primary tumor rejection in a prophylactic setting instead of therapeutic setting (46), but 
with our metastatic model there might be more clinical benefit from prophylactic vaccination 
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with tumor-reactive reprogrammed immune cells on preventing relapse or distant metastasis. 
This is supported by the cross-reactivity exhibited by the cytotoxicity and IFN-γ production 
against primary or relapsing forms of tumors upon metastasis, where the cells have not 
necessarily changed so much that the multi-faceted anti-tumor immune response would be 
evaded. The retained effective cytotoxicity against all four tumors despite a change in tumor site 
provides further evidence for the use of reprogrammed splenocytes as a preventive vaccine 
against recurrence to prolong cancer-free survival. If peripheral blood was collected from 
patients before conventional therapy for cryopreservation and then expanded for subsequent 
ACT following various treatments, the vaccination could greatly benefit the long-term anti-tumor 
immune response in patients, resulting in potential recurrence or metastasis prevention for some 
time by conferring a response against circulating or disseminated tumor cells. New drug-targeted 
methods of therapy for metastatic disease have focused on the many steps of the metastatic 
cascade for inhibition of tumor growth, the associated soluble factors (like VEGF) or affecting 
the tumor compatibility with the surrounding TME of the pre-metastatic niche (11). If the ACT 
was administered in concert with some of these targeted methods against the permissive TME, a 
longer distant recurrence free interval may be achieved to prolong survival through synergistic or 
sequential therapeutic effects.  
In the context of prevention, highly effective cancer vaccines or therapeutics have not 
been developed since the success of prophylactic vaccination (nearly 100% efficacy) with human 
papillomavirus (HPV) virus-like particles in 2006, providing humoral immunity against variants 
known to cause cervical cancer (83). Other groups have had success in the field of cancer 
vaccine performance when providing T-helper peptides specific for HER2/neu extracellular 
domains to prime a humoral response that resulted in epitope spreading (55, 56). Recently, Sun 
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et al. (38) studied the clinical use of expanded activated autologous lymphocytes from the 
peripheral blood on metastatic breast cancer following adjuvant therapy and observed a response 
during 25-month period (progression free disease or stable disease) in 3 out of 4 stage IV breast 
cancer patients to prolong overall survival (median: 11.5 months). The metastatic breast cancer 
patients also showed significant increased CD8+ Cytotoxic T lymphocytes (CTL), Natural Killer 
(NK) and NKT cells following infusion (38). Also, Domschke et al. (37) has found that 
metastatic breast cancer patients with pre-existing tumor reactive bone marrow memory T cells 
could receive effective ACT with T cells that have been reactivated with autologous MCF7 
breast cancer lysate-pulsed dendritic cells. Almost half the patients (44%) had de novo induction 
of tumor-reactive memory T cells in the peripheral blood following ACT as a positive response 
to immunotherapy (37). Longer survival was associated with a positive immunologic response to 
ACT, a prior high-level tumor-reactive bone marrow T cell population and a higher estimated 
number of transferred tumor-reactive T cells (37). These correlations, along with the 
consideration of separating stage IV patients novice to treatment from disease recurrence patients 
refractory to treatment (2), provide important treatment considerations for metastatic breast 
cancer patients moving forward. The ideas put forth by Seong and Matzinger (84) combining the 
Danger and Self/Nonself models, by considering the access to cryptic immunogenic epitopes 
induced by cellular stress, highlighted the need for the quality of the avid immune response to 
many antigenic targets (similar to humoral epitope spreading (55)) instead of the quantitative 
high-affinity immune response against a single antigen, like overexpressed neu protein. This 
strategy of including cryptic epitopes that have not been involved in thymic selection following 
danger signaling (54) may have bearing on the elicited immune reponse to metastatic tumor cells 
that have undergone massive changes during relapse or distant site deposition. Pioneering work 
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done by June and colleagues with leukemia or HIV treatments using ACT has attracted more 
attention to the field with an impressive level of success in responders for the induction of 
remission or long-term responses (85). Recently, Kumar et al. (86) investigated a prophylactic 
strategy with aggressive leukemia treatment using donor leukocyte infusion against recurrence to 
find that 25% of patients that received leukocytes in addition to stem cell therapy achieved 
complete remission. While the option of prophylactic use of donor-derived ACT during minimal 
residual disease in aggressive hematologic malignancies may not be much more useful at 
warding off relapse or prolonging survival than current treatment plans due to GVHD, the 
strategy using autologous lymphocytes may still be useful in other forms of cancer at least as an 
alternative in more appropriate forms of cancer for immunologic responders. The preventive use 
of ACT, providing ex vivo expanded autologous tumor-reactive immune cells comprised of 
innate (NK/NKT cells) and adaptive components (CD8+ central memory T cells), has not 
previously been proposed in metastatic or recurrent breast cancer models. When considering 
current metastatic breast cancer treatment modalities (5, 87-89) or the challenges to provide 
novel therapeutics that consider TME influence (90, 91), this new preventive strategy could be 
an effective form of immunotherapy at prolonging survival following surgery, radiation and/or 
chemotherapy. After primary tumor removal and confirmation of minimal residual disease, this 
prophylactic treatment may be effective at boosting the immediate innate anti-tumor immune 
response, skewing it towards elimination of any disseminated or circulating tumor cells, and 
providing a long-term adaptive memory response against recurrence. In addition, it also may 
fulfill a niche when other treatments initially fail (like Trastuzumab) due to refractory disease or 
dependent on the suppressed host immune response.  
 
 










We have outlined the changes associated with metastasis of mouse mammary carcinoma 
compared to metastatic relapse of its antigen negative variant. The stable changes in the tumor 
cells resemble a stem-like dedifferentiation to harness the mammalian machinery employed in 
the deposition of normal stem cells to various tissues based on neu expression. The stem-like 
changes to tumor were most likely induced by epigenetic changes in mMMC instead of selective 
enrichment of clones. The TME has been implied to be involved in a crosstalk with the tumor 
cells driving the changes observed, including the rate of macrometastatic tumor initiation or 
tumorigenicity in vivo. The immunosuppressive MDSC levels were not increased in association 
with lung metastasis in our model, contrary to the previously described s.c. tumor site. The 
metastasis-derived changes also appear to be functionally beneficial to the cell survival in the 
lung TME or back in the s.c. TME, but the multi-antigenic signature recognized by the anti-
tumor immune response was not lost against MMC or ANV. The B/I + γ-c expansion protocol 
effectively reprograms and phenotypically differentiates splenocytes towards activated NK/NKT 
cells and TCM cells sensitized by mMMC or mANV, despite tumor site. These tumor-reactive 
splenocytes also effectively produce IFN-γ and an in vitro cytotoxic effect towards primary or 
metastatic tumor. We propose a preventive treatment strategy of ex vivo reprogrammed tumor-
reactive immune cells that could be effectively employed to prevent the relapse or metastasis of 
mouse mammary carcinoma in the preclinical setting, hopefully translating to prolonged patient 
survival in the clinical setting, when other treatment modalities prove ineffective. 
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